Cargando…

Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience

OBJECTIVE: Lutetium-177 prostate-specific membrane antigen-617 is a novel alternative therapeutic option in metastatic castration-resistant prostate cancer, especially useful for patients who do not respond to standard therapy methods. The aim of this study was to define the efficacy and safety prof...

Descripción completa

Detalles Bibliográficos
Autor principal: Maman, Adem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Atatürk University School of Medicine 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440926/
https://www.ncbi.nlm.nih.gov/pubmed/37403908
http://dx.doi.org/10.5152/eurasianjmed.2023.0055
_version_ 1785093259055333376
author Maman, Adem
author_facet Maman, Adem
author_sort Maman, Adem
collection PubMed
description OBJECTIVE: Lutetium-177 prostate-specific membrane antigen-617 is a novel alternative therapeutic option in metastatic castration-resistant prostate cancer, especially useful for patients who do not respond to standard therapy methods. The aim of this study was to define the efficacy and safety profile of lutetium-177 prostate-specific membrane antigen-617 treatment in a group of patients with metastatic castration-resistant prostate cancer. MATERIALS AND METHODS: Study group included 34 men with metastatic castration-resistant prostate cancer (median, 69.6 ± 7.7 years) who were treated with lutetium-177 prostate-specific membrane antigen-617 therapy (22/34; 4 courses, 12/34; 2 courses). Patients were evaluated by physical examination, Eastern cooperative oncology group performance status, gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography, brief pain inventory-short form questionnaire, biochemical tests, and complete blood counts. Treatment response and adverse effects were examined by brief pain inventory scores, SUV(max) values, biochemical tests, and complete blood counts. Independent variables were analyzed statistically (significance; P < .05). RESULTS: The Eastern cooperative oncology group performance was grade 0 in 5/34 (14.7%), grade 1 in 25/34 (73.5%), and grade 2 in 4/34 (11.8%) patients. Distribution of patient numbers according to brief pain inventory scores (score: <1, scores: 1-4, and scores: 5-10) was 2, 10 and 22 at the beginning, 6, 16 and 12 after the second course, and 10, 10 and 2 after the fourth course of treatment, respectively. Serum prostate-specific antigen decreased in 15 of 22 patients (68%) (P < .05). Before and after the treatment, we found a substantial decrease in SUV(max) values (22.3 vs. 11.8, P < .001) and brief pain inventory scores (score ≥ 5; 22/34 pts vs. 0/22 pts). The counts of white blood cells (P < .05), hemoglobin (P < .05), and thrombocytes (P = .001) were all significantly lower at the conclusion of the therapy. The most important adverse events were severe leukopenia (1/34 pts; 2.29 × 10(3)/µL) and thrombocytopenia (3/34 pts; 32 000, 36 000, 32 000 × 10(6)/L). CONCLUSION: We found that lutetium-177 prostate-specific membrane antigen-617 therapy is a promising treatment method for metastatic castration-resistant prostate cancer patients who are unresponsive to conventional therapy, according to our biochemical, positron emission tomography/computed tomography, and pain score outcomes.
format Online
Article
Text
id pubmed-10440926
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Atatürk University School of Medicine
record_format MEDLINE/PubMed
spelling pubmed-104409262023-08-22 Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience Maman, Adem Eurasian J Med Original Article OBJECTIVE: Lutetium-177 prostate-specific membrane antigen-617 is a novel alternative therapeutic option in metastatic castration-resistant prostate cancer, especially useful for patients who do not respond to standard therapy methods. The aim of this study was to define the efficacy and safety profile of lutetium-177 prostate-specific membrane antigen-617 treatment in a group of patients with metastatic castration-resistant prostate cancer. MATERIALS AND METHODS: Study group included 34 men with metastatic castration-resistant prostate cancer (median, 69.6 ± 7.7 years) who were treated with lutetium-177 prostate-specific membrane antigen-617 therapy (22/34; 4 courses, 12/34; 2 courses). Patients were evaluated by physical examination, Eastern cooperative oncology group performance status, gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography, brief pain inventory-short form questionnaire, biochemical tests, and complete blood counts. Treatment response and adverse effects were examined by brief pain inventory scores, SUV(max) values, biochemical tests, and complete blood counts. Independent variables were analyzed statistically (significance; P < .05). RESULTS: The Eastern cooperative oncology group performance was grade 0 in 5/34 (14.7%), grade 1 in 25/34 (73.5%), and grade 2 in 4/34 (11.8%) patients. Distribution of patient numbers according to brief pain inventory scores (score: <1, scores: 1-4, and scores: 5-10) was 2, 10 and 22 at the beginning, 6, 16 and 12 after the second course, and 10, 10 and 2 after the fourth course of treatment, respectively. Serum prostate-specific antigen decreased in 15 of 22 patients (68%) (P < .05). Before and after the treatment, we found a substantial decrease in SUV(max) values (22.3 vs. 11.8, P < .001) and brief pain inventory scores (score ≥ 5; 22/34 pts vs. 0/22 pts). The counts of white blood cells (P < .05), hemoglobin (P < .05), and thrombocytes (P = .001) were all significantly lower at the conclusion of the therapy. The most important adverse events were severe leukopenia (1/34 pts; 2.29 × 10(3)/µL) and thrombocytopenia (3/34 pts; 32 000, 36 000, 32 000 × 10(6)/L). CONCLUSION: We found that lutetium-177 prostate-specific membrane antigen-617 therapy is a promising treatment method for metastatic castration-resistant prostate cancer patients who are unresponsive to conventional therapy, according to our biochemical, positron emission tomography/computed tomography, and pain score outcomes. Atatürk University School of Medicine 2023-06-01 /pmc/articles/PMC10440926/ /pubmed/37403908 http://dx.doi.org/10.5152/eurasianjmed.2023.0055 Text en © Copyright 2023 authors https://creativecommons.org/licenses/by/4.0/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Original Article
Maman, Adem
Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience
title Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience
title_full Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience
title_fullStr Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience
title_full_unstemmed Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience
title_short Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience
title_sort lutetium-177 prostate-specific membrane antigen-617 treatment in metastatic castration-resistant prostate adenocarcinoma: results of single-center experience
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440926/
https://www.ncbi.nlm.nih.gov/pubmed/37403908
http://dx.doi.org/10.5152/eurasianjmed.2023.0055
work_keys_str_mv AT mamanadem lutetium177prostatespecificmembraneantigen617treatmentinmetastaticcastrationresistantprostateadenocarcinomaresultsofsinglecenterexperience